Brief: Noxopharm Ltd Says US FDA Grants Orphan Drug Designation For CRO-67
04/10/2023 24:30
Oct 4 (Reuters) - Noxopharm Ltd NOX.AX :
* US FDA GRANTS ORPHAN DRUG DESIGNATION FOR CRO-67
Source text for Eikon: ID:nASXbCw4K6
Further company coverage: NOX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Noxopharm
See all newsBrief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential
Brief: Noxopharm Says New Data Confirms Cancer-Fighting Potential
Brief: Noxopharm Appoints Dr Olivier Laczka As New CEO
Brief: Noxopharm Ltd Announces Resignation Of Chief Executive Officer